Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH ± Rituximab + Ponatinib in Newly-Diagnosed Ph+ ALL
NCT07224100Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by University of Washington. Primary endpoint: Rate of complete molecular response at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT07224100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224100.